Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WD-1602 vs Pradaxa Bioequivalence Study in Fed Healthy Subjects
NCT04592822Phase 1Unknown
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of WD-1602 in thromboembolism (2 arms), sponsored by Shanghai WD Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t at Day 3, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at Day 3 and 1 more. Status: unknown.
02
Drugs
WD-1602
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04592822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592822.